Additional milestone payments of up to approximately USD 1.125 billion may also be made, according to a press release.
Ollin is developing the antibody OLN324, which is currently in phase 3 trials for the eye conditions wet age-related macular degeneration (wet AMD) and diabetic macular oedema.
Johnson & Johnson has also entered into a separate financing agreement with Blackstone Life Sciences, which will contribute a total of USD 750 million towards the phase 3 development programme. In return, Blackstone will be entitled to milestone payments and royalty payments.